Please login to the form below

Not currently logged in

Deal Watch table for January 2015

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

This table lists all the major pharma collaborations, acquisitions and mergers agreed during January 2014.

For an indepth analysis of these deals, read 'Pharma deals during January 2015'

Licensor acquired / licensee acquirer

Product / technology

Deal type

Headline ($m)

NPS/ShireNPS specialises in rare diseases including Gattex [teduglutide] for the treatment of short bowel syndromeCorporate acquisition5,200
Foundation Medicine/RocheBroad R&D collaboration to optimise oncology treatments via Foundations genomic analysis and molecular informationMajority interest acquisition1,180
Kite Pharma/AmgenChimeric Antigen Receptor (CAR) T cell immunotherapy engineered autologous cell therapy (eACT) platform, Amgen contribute cancer targetsLicence collaboration agreement1,110
Janssen/ DepomedNucynta [tapentadol] franchise including extended release tablets and oral solutionsDivestment of US rights
Esteve/ MundipharmaDiscovery and development of next generation pain products including E-52862 in P2 for neuropathic painStrategic collaboration1,000
Isis/ JanssenAntisense drugs to treat autoimmune disorders of the GI tract - local and oral therapies (3 programmes)Collaboration to discover and develop candidates835
Fedora and Meiji Seika/RocheRoche secures rights to OP0595 a beta lactamase inhibitor in P1 clinical development against multi drug resistant bacteriaLicence agreement
Convergence/Biogen IdecIncludes a neuropathic pain portfolio with CNV 1014802 in P2 for trigeminal neuralgiaCorporate acquisition675
Trophos/RocheIncludes Olesoxime an orphan drug in P2 for spinal muscular atrophy; plus TRO 40303 in P1 for cardiac injuryCorporate acquisition545
Cytos Biotechnology/ OnCoreAccess to virus like particle (VLP) platform for the treatment and prevention of hepatitis B with an option to other viral diseasesExclusive licence522
AC Immune/ JanssenTo develop and commercialise therapeutic anti-Tau vaccines [ACI35, P1] for the treatment of Alzheimer's disease3 year research collaboration and exclusive licence509
Neuropore Therapies/UCBTo develop and commercialise NPT200-11 and other therapeutic products for Parkinson's diseaseCollaboration agreement
PneumRx/BTGIncludes RePneu a coil to open airways in emphysema patientsCorporate acquisition475
Phenex/GileadSmall molecules targeting FXR Farnesoid X receptor (FXR) programme Px102, Px104 in P2 development in Non-Alcoholic Steatohepatitis [NASH]Asset acquisition470
Auden Mckenzie/ActavisPurchase includes generic portfolio of 175 products making Actavis no 1 generic supplier in the UKCorporate acquisition458
Agenus/IncyteUsing Agenus' antibody discovery platform focusing on 4 checkpoint modulator programmes includes $35m equityLicence to develop and commercialise410
Aurigene /Curis2 programmes including IRAK4 Inhibitors and small molecule antagonist of programmed death [PD-L1]Collaboration and option to a licence346
Vedanta /J&JMicrobiome-based drug candidate VE202 for bowel diseases, Crohn's disease and ulcerative colitisLicence to develop anti-bacterial VE202241
OnCyte/Cardio3Acquisition of the oncology division of Celdara Medical including CM-CS1 an autologous CAR-T cell drug candidate which uses NKG2D to target tumour antigensAsset acquisition180
ZymeWorks/CelgeneDevelopment of multiple bi-specific antibodies using the Azymetric platformLicence, option and collaboration164
Novartis/AspenPurchase of the heparin based anticoagulant Mono-Embolex, with sales of €68m in 2013Asset acquisition142
 Amunix/NaiaTo develop glucagon peptide agonists GLP-1-XTEN and GLP-2-XTEN in T2 diabetes and short bowel syndrome2 exclusive licences140 

The Deal Watch table is compiled by Medius Associates

11th February 2015

The Deal Watch table is compiled by Medius Associates

11th February 2015

From: Research, Sales



Career advice

No results were found

Subscribe to our email news alerts

Featured jobs


Add my company
11 London

We live in a hyper-connected world. This has clear benefits for the health of our communities, our businesses and our...